» Articles » PMID: 33186615

Effects of Ultra-high Doserate FLASH Irradiation on the Tumor Microenvironment in Lewis Lung Carcinoma: Role of Myosin Light Chain

Abstract

Purpose: To investigate whether the vascular collapse in tumors by conventional dose rate (CONV) irradiation (IR) would also occur by the ultra-high dose rate FLASH IR.

Methods And Materials: Lewis lung carcinoma (LLC) cells were subcutaneously implanted in mice. This was followed by CONV or FLASH IR at 15 Gy. Tumors were harvested at 6 or 48 hours after IR and stained for CD31, phosphorylated myosin light chain (p-MLC), γH2AX (a surrogate marker for DNA double strand break), intracellular reactive oxygen species (ROS), or immune cells such as myeloid and CD8α T cells. Cell lines were irradiated with CONV IR for Western blot analyses. ML-7 was intraperitoneally administered daily to LLC-bearing mice for 7 days before 15 Gy CONV IR. Tumors were similarly harvested and analyzed.

Results: By immunostaining, we observed that CONV IR at 6 hours resulted in constricted vessel morphology, increased expression of p-MLC, and much higher numbers of γH2AX-positive cells in tumors, which were not observed with FLASH IR. Mechanistically, MLC activation by ROS is unlikely, because FLASH IR produced significantly more ROS than CONV IR in tumors. In vitro studies demonstrated that ML-7, an inhibitor of MLC kinase, abrogated IR-induced γH2AX formation and disappearance kinetics. Lastly, we observed that CONV IR when combined with ML-7 produced some effects similar to FLASH IR, including reduction in the vasculature collapse, fewer γH2AX-positive cells, and increased immune cell influx to the tumors.

Conclusions: FLASH IR produced novel changes in the tumor microenvironment that were not observed with CONV IR. We believe that MLC activation in tumors may be responsible for some of the microenvironmental changes differentially regulated between CONV and FLASH IR.

Citing Articles

Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma.

Li H, Tang R, Shi H, Qin Z, Zhang X, Sun Y Signal Transduct Target Ther. 2025; 10(1):82.

PMID: 40032871 PMC: 11876629. DOI: 10.1038/s41392-025-02184-0.


Instantaneous dose rate as a crucial factor in reducing mortality and normal tissue toxicities in murine total-body irradiation: a comparative study of dose rate combinations.

Zhu H, Liu S, Qiu J, Hu A, Zhou W, Wang J Mol Med. 2025; 31(1):79.

PMID: 40011844 PMC: 11866584. DOI: 10.1186/s10020-025-01135-3.


FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.

Ni H, Reitman Z, Zou W, Akhtar M, Paul R, Huang M Nat Cancer. 2025; .

PMID: 39910249 DOI: 10.1038/s43018-025-00905-6.


Exploring the Metabolic Impact of FLASH Radiotherapy.

Geirnaert F, Kerkhove L, Montay-Gruel P, Gevaert T, Dufait I, De Ridder M Cancers (Basel). 2025; 17(1.

PMID: 39796760 PMC: 11720285. DOI: 10.3390/cancers17010133.


FLASH radiotherapy: mechanisms, nanotherapeutic strategy and future development.

Wang Y, Wang H, Hu J, Chai J, Luan J, Li J Nanoscale Adv. 2025; 7(3):711-721.

PMID: 39781242 PMC: 11705069. DOI: 10.1039/d4na00753k.